Maraviroc Waymade (Maraviroc)

Maraviroc works by selectively binding to the CCR5 chemokine receptor on CD4⁺ T‑cells, blocking the entry of CCR5‑tropic HIV‑1 strains. This inhibition prevents the virus from fusing with the host cell, thereby stopping replication and limiting disease progression.

The dosage of Maraviroc Waymade is determined by the prescribing clinician based on individual patient factors, including viral tropism, concomitant medications, and renal or hepatic function. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for Maraviroc in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against unknown risks and consider alternative therapies when possible. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Maraviroc belongs to the CCR5 antagonist class, offering a distinct mechanism from nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors. It is particularly useful for patients with CCR5‑tropic virus or those needing an alternative pathway to overcome resistance to other drug classes.

Maraviroc Waymade tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme heat or humidity.

Maraviroc Waymade is taken orally, usually with food to improve absorption. The tablet should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include severe liver injury, allergic reactions such as anaphylaxis, QT interval prolongation leading to cardiac arrhythmias, and rare but life‑threatening skin conditions like Stevens‑Johnson syndrome. Patients should report any unusual symptoms promptly to their clinician.

Maraviroc Waymade should not be used in patients whose HIV‑1 strain does not use the CCR5 co‑receptor, as it will be ineffective. It is also contraindicated in individuals with known hypersensitivity to Maraviroc or any of its excipients.